| Filed On | Filing |
|---|---|
| 08 Nov 2024 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On August 8, 2024, Agenus Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Report”) to disclose the appointment of Thomas L. Harrison to the Company’s Board of Directors (the “Board”). At the time of filing, the Boa... |
| 11 Sep 2015 |
8-K/A: Financial Statements and Exhibits
The Note Purchase Agreement is not intended to provide any factual information about the Company. The Note Purchase Agreement contains representations, warranties and covenants that the Company and Oberland made to each other as of speci... |
| 29 Apr 2014 |
8-K/A: Financial Statements and Exhibits
We have audited the accompanying financial statements of 4-Antibody AG, which comprise the statement of financial position as of 31 December 2013 and 2012, and the related statements of comprehensive income, changes in equity and cash fl... |
| 23 Oct 2012 |
8-K/A: Other Events
Agenus Commences Phase 2 Study of HerpV Vaccine for the Treatment of Genital Herpes |
| 29 Jan 2001 |
8-K/A: Financial Statements and Exhibits
In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, shareholders' equity and cash flows present fairly, in all material respects, the financial position of Aquila Biopharmac... |
Loading...